onary artery disease during coronary angiography and, when present, is a predictor of mortality. The question as to whether opening these occlusions improves clinical outcomes continues to be debated 40 years after percutaneous coronary intervention (PCI) was introduced. Extensive non-randomized registry data have suggested improved symptomatic outcomes as well as quality of life measures, but as yet with no suggestion of survival benefit, left ventricular function improvement, or decline in rates of myocardial infarction (MI). 2 Arguments against opening CTOs include: 'It is already occluded and can't get any worse', 'it is worthless to open because most of the muscle must already be non-viable', 'there is no need to intervene even if there is viable myocardium because the collateral circulation will suffice'. However, the counter argument is stronger: 'CTOs frequently serve viable myocardium and they are all flow limiting', and the pressure distal to a CTO is always very low even when collateral circulation has been established. Therefore, in the symptomatic patient, opening a CTO serving viable myocardium should have a similar benefit to opening a stenotic lesion. In order to study the opening of CTOs, two randomized trials have been conducted using the Seattle Angina Questionnaire (SAQ) to measure symptomatic improvement. One of them, the EuroCTO trial, is reported in this issue of the European Heart Journal by Werner et al. 3 Does it bring light to the occluded tunnel, or are we sleeping through the problems of an open-labelled trial using subjective endpoints? This trial was structured to evaluate patients with a single CTO lesion and no other disease, as well as those with a CTO lesion plus other stenoses (52%), but those stenoses were stented prior to randomization. So, the objective was to judge the value of opening the CTO independently of other co-existing obstructions. It was a prospective, open-labelled trial of 396 patients randomized with a 2:1 ratio to PCI or optimal medical therapy (OMT). The primary endpoint was a change to the SAQ scores. In the PCI group, 13.4% of the procedures were failures, and in the OMT group, 7.3% underwent PCI. Analysis was by intention to treat. At 12 months, the angina frequency and quality of life measures were significantly better in the PCI group. Patients in the PCI group reported complete freedom from angina (71.6%) compared with those in the OMT group (57.8%). Although this trial was terminated prematurely due to slow enrolment, and fell far short of the original goal of 1200 patients, it is the first randomized trial to show significant symptomatic improvement. This finding supports the clinical experience of many interventional cardiologists. Is this the light at the end of the tunnel? (or, perhaps at the beginning of the tunnel if a retrograde approach is used?) Alternatively, are we sleeping and not applying appropriate scepticism toward an open-label, unblinded assessment of patientreported health status using the SAQ?
Although CTO is commonly encountered in patients undergoing coronary arteriography, these lesions are infrequently treated by PCI, and CTO is a major factor in referral for cornary artery bypass graft (CABG) surgery. Historically the low success rate, prolonged procedures, fear of contrast-induced nephropathy, or radiation injury have been impediments to performing CTO PCI. Advances in the technical performance of CTO PCI in recent years including improved wires and wire techniques, specific crossing devices, dissection and re-entry methods, dual injection of contralateral coronary arteries, and the retrograde techniques have enabled success rates approaching 90% among highly experienced operators. These advances have highlighted the interest in treating CTOs and have spawned a new group of CTO operators. Thus, CTO PCI can be done, and the remaining questions are should it be done and in which patients?
Another randomized trial, the DECISION-CTO (Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients with Chronic Total Occlusion; http://www.clinicaltrials.gov. Unique identifier: NCT01078051) which aimed to enrol 1284 patients was prematurely halted, similarly to the EuroCTO trial due to slow enrolment. A total of 834 patients were randomized to CTO PCI or OMT alone. At 3 years, the primary endpoint of death, MI, stroke, or repeated revascularization occurred in 19.6% of the OMT vs. 21.4% of the CTO PCI group [adjusted hazard ratio (HR) 0.91, 95% confidence interval (CI) 0.68-1.23, P = 0.54]. Although these observations supported the non-inferiority of OMT compared with CTO revascularization, a number of study limitations need to be taken into consideration before drawing any definite conclusions regarding the value proposition for CTO PCI such as the: (i) high crossover rates; (ii) primary endpoint related to hard endpoints rather than symptomatic angina relief; and the (iii) high percentage of non-CTO lesions without prior evidence of ischaemia or symptoms. Another randomized trial is the EXPLORE trial 4 
(Evaluating Xience and Left Ventricular
Function in Percutaneous Coronary Intervention on Occlusions After ST-Elevation Myocardial Infarction) which randomized 304 patients who underwent primary PCI for ST-elevation myocardial infarction and had a concomitant non-infarct-related CTO to OMT or CTO PCI at 7 days after treating the culprit vessel. Both the primary endpoint of magnetic resonance imaging (MRI)-derived left ventricular ejection fraction and end-diastolic volume, as well as the secondary hard clinical endpoint of cardiac death, MI, or CABG were comparable at 4 months in both groups. 5 Along with the inconclusive results from recent randomized trials, observational studies conducted over the last decade have not been able to show convincing incremental benefits of CTO PCI over OMT due to selection and ascertainment bias. Nevertheless, the Italian Registry of Chronic Total Occlusions, 6 which is the largest observational study thus far, enrolled 1777 CTO patients and at 1-year both cardiac death and major adverse cardiovascular events were lower in the CTO PCI compared with the OMT group. 6 Therefore evidence is still lacking to support the recommendation that PCI be applied to CTO lesions to modify mortality or MI rates. For syptomatic patients, the judgement must be informed by the understanding of the relative benefit and risk based on many factors including: coronary anatomy and lesion complexity, viability of distal myocardial beds, symptomatic response to medical antianginal therapy, as well as the risk of complications. On what evidence can we base our recommendations to patients that their symptoms will be significantly improved by stenting over OMT? The current study supports the conclusion that PCI is superior to OMT, but is that result due to a physiological or psychological mechanism? Perhaps it does not matter. 'If my patient feels better, that is good enough'. On the other hand, in the interest of medical resource utilization and patient safety, it would be helpful if the true impact of the procedure could be proved. The ORBITA 7 trial using sham control methodology for significant coronary stenosis intervention could not show a symptomatic benefit over OMT alone. That trial has been discussed extensively, but the value of a sham comparison therapy may be in teasing out the mechanisms of change in subjective endpoints. It appears that CTO is a prime candidate for a sham-controlled trial. If the entry criteria were sufficiently rigorous, a clear benefit of stenting CTO lesions might be proved. Given the poor enrolment in the recently conducted trials, some will say that performing such a study would be impossible. On the other hand, a well-supported clinical research plan to solve the CTO conundrum (Take home figure) could not only answer the question of 'should it be done?', but perhaps 'to whom should it be done?', and even give answers to the most important unanswered question, 'are there patients with CTO who can benefit from PCI to reduce hard cardiac events?' The EuroCTO trial has shed additional light on the occluded tunnel, but we must not yet go to sleep.
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